Who
Daniel S. Lorrain
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Contineum Therapeutics.
In numbers
- Trades disclosed
- 80
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $2.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 May 2024
- Last trade
- 9 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2525 at $1.01 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $40025 at $16.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —25 at $0.00 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $2525 at $1.01 | filing |
| 9 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $40025 at $16.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $1,0251,015 at $1.01 | filing |
| 8 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K1,015 at $16.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,015 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,015 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $1,0251,015 at $1.01 | filing |
| 8 Jul 2026filed 10 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K1,015 at $16.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $4,2254,183 at $1.01 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,183 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $92K5,852 at $15.67 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K2,501 at $16.24 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,183 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Code M | $4,2254,183 at $1.01 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $92K5,852 at $15.67 | filing |
| 1 Jul 2026filed 2 Jul 2026 | CTNM Contineum TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K2,501 at $16.24 | filing |
News
Vaxart (OTCMKTS:VXRT) versus Contineum Therapeutics (NASDAQ:CTNM) Head to Head ReviewCTNM · themarketsdaily.com · 13 Oct 2026Contineum Therapeutics (NASDAQ:CTNM) Reaches New 1-Year Low – Time to Sell?CTNM · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Daniel S. Lorrain; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.